1. Scrip
  2. >>Business

Pfizer, Serum File EUAs For COVID-19 Vaccines In India

Questions Remain Over Serum's Adverse Event

 
• By Vibha Ravi

Pfizer and separately Serum Institute, which is partnering Oxford/AstraZeneca's COVID-19 candidate, have filed for emergency use authorizations of their vaccines in India. While Pfizer is yet to conduct clinical trials in India, questions over a serious adverse event during Serum's trials linger despite the regulator's clean chit.

As COVID-19 Vaccines Zip Ahead To Launch, Questions Linger • Source: Shutterstock

Pfizer Ltd. (India) and Serum Institute of India Pvt. Ltd. filed for emergency use authorizations of their COVID-19 vaccines in India over the 5-6 December weekend. While the Pfizer Inc./BioNTech SE mRNA candidate recently became the first vaccine to be approved in the UK, it hasn't been in clinical trials in India and it remains to be seen if the US firm's Indian subsidiary will be directed to conduct limited local trials before approval.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Asia Deal Watch: Daiichi Taps Into Wayfinder’s RNA-Encoding Platform

 
• By Jung Won Shin, Lisa Takagi, Joseph Haas, Anju Ghangurde, and Vibha Ravi

Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.

Cancer Retains Top Spots In Alliance Deal Volume, Value

 
• By Joseph Haas

Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

More from Scrip

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.